0.6505
전일 마감가:
$0.6552
열려 있는:
$0.6655
하루 거래량:
138.69K
Relative Volume:
0.60
시가총액:
$59.97M
수익:
-
순이익/손실:
$-30.15M
주가수익비율:
-0.7148
EPS:
-0.91
순현금흐름:
$-31.63M
1주 성능:
+12.96%
1개월 성능:
+12.71%
6개월 성능:
-38.05%
1년 성능:
-64.06%
Context Therapeutics Inc Stock (CNTX) Company Profile
명칭
Context Therapeutics Inc
전화
267-225-7416
주소
2001 MARKET STREET, PHILADELPHIA
CNTX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CNTX
Context Therapeutics Inc
|
0.631 | 59.97M | 0 | -30.15M | -31.63M | -0.91 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
456.82 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.35 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
555.67 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
246.00 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-21 | 개시 | William Blair | Outperform |
2025-01-08 | 개시 | JMP Securities | Mkt Outperform |
2024-11-25 | 개시 | D. Boral Capital | Buy |
2024-05-16 | 개시 | Piper Sandler | Overweight |
Context Therapeutics Inc 주식(CNTX)의 최신 뉴스
Citadel Advisors LLC Makes New $31,000 Investment in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Millennium Management LLC Purchases 34,835 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Context Therapeutics Approves Reverse Stock Split Amendment - TipRanks
Context Therapeutics Names Dr. Karen Chagin as Chief Medical Officer - MSN
Co-Founder of Context Therapeutics Martin Lehr Buys 10% More Shares - simplywall.st
Context Therapeutics Executives Increase Holdings - TradingView
Context Therapeutics: Undervalued Cancer Fighter (NASDAQ:CNTX) - Seeking Alpha
Jane Street Group LLC Makes New $29,000 Investment in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
CNTXContext Therapeutics Reports First Quarter 2025 Operating and Financial Results - mx.advfn.com
Northern Trust Corp Sells 58,946 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Context Therapeutics Inc. Advances CTIM-76 in Phase 1 Trial for Solid Tumors with Initial Data Expected in 2026 - Nasdaq
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting - GlobeNewswire
Context Therapeutics' Cancer Drug CTIM-76 Progresses in Phase 1 Trial: Key Updates from ASCO 2025 - Stock Titan
Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa
Context Therapeutics (CNTX) Names New Chief Medical Officer | CN - GuruFocus
Context Therapeutics (CNTX) Names New Chief Medical Officer | CNTX Stock News - GuruFocus
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - GlobeNewswire
Context Therapeutics Appoints Developer of First FDA-Approved Solid Tumor Cell Therapy as Chief Medical Officer - Stock Titan
Context Therapeutics Grants Stock Options to New Hires as Part of Strategic Talent Growth - MSN
Context Therapeutics Names Dr. Karen Smith as Interim Chief Medical Officer - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Consensus Price Target from Analysts - Defense World
Context Therapeutics Reports Q1 2025 Financial Results and Clinical Progress - MSN
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
William Blair Has Positive Outlook of CNTX FY2025 Earnings - Defense World
Research Analysts Offer Predictions for CNTX Q2 Earnings - Defense World
D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
UTR Therapeutics files IND application for UTRxM1-18 for c-MYC-driven cancers - BioWorld MedTech
Context Therapeutics Showcases Promising CT-95 Data at AACR Annual Meeting - MSN
Context Therapeutics (CNTX) Receives Continued 'Buy' Rating from Analyst | CNTX Stock News - GuruFocus
FORE Biotherapeutics’ Plixorafenib Study to Be Highlighted at ASCO 2025 - MyChesCo
CONTEXT THERAPEUTICS Earnings Results: $CNTX Reports Quarterly Earnings - Nasdaq
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results - GlobeNewswire
Marshall Wace LLP Buys New Stake in Context Therapeutics Inc. (NASDAQ:CNTX) - The AM Reporter
Context Therapeutics Appoints Karen Smith as Interim CMO - citybiz
Context Therapeutics (CNTX) Names Karen Smith as Interim Chief Medical Officer | CNTX Stock News - GuruFocus
Context Therapeutics appoints new interim CMO - Investing.com
Context Therapeutics appoints new interim CMO By Investing.com - Investing.com South Africa
Context Therapeutics Announces Chief Medical Officer Transition - GlobeNewswire
Context Therapeutics Inc Announces Executive Changes Effective May 10, 2025 - marketscreener.com
Renaissance Technologies LLC Boosts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
What is William Blair’s Estimate for CNTX Q2 Earnings? - Defense World
Context Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Boosted by Geode Capital Management LLC - Defense World
Context Therapeutics’ (CNTX) Outperform Rating Reiterated at William Blair - Defense World
Context Therapeutics’ (CNTX) Buy Rating Reiterated at D. Boral Capital - Defense World
Context Therapeutics Inc (CNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Context Therapeutics Inc 주식 (CNTX) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
자본화:
|
볼륨(24시간):